Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Shunchuan Zhang & Samuel D Rabkin. (2021) The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?. Expert Opinion on Drug Discovery 16:4, pages 391-410.
Read now
Read now
Roland E. Kontermann, Guy Ungerechts & Dirk M. Nettelbeck. (2021) Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. mAbs 13:1.
Read now
Read now
Adrian Pelin, Stephen Boulton, Levi A. Tamming, John C. Bell & Ragunath Singaravelu. (2020) Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. Expert Opinion on Biological Therapy 20:9, pages 1083-1097.
Read now
Read now
Matthew Chiu, Edward John Lloyd Armstrong, Vicki Jennings, Shane Foo, Eva Crespo-Rodriguez, Galabina Bozhanova, Emmanuel Christian Patin, Martin McLaughlin, David Mansfield, Gabriella Baker, Lorna Grove, Malin Pedersen, Joan Kyula, Victoria Roulstone, Anna Wilkins, Fiona McDonald, Kevin Harrington & Alan Melcher. (2020) Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opinion on Biological Therapy 20:6, pages 635-652.
Read now
Read now
Lino E. Torres-Domínguez & Grant McFadden. (2019) Poxvirus oncolytic virotherapy. Expert Opinion on Biological Therapy 19:6, pages 561-573.
Read now
Read now
Chun-Yu Chen, Brian Hutzen, Mary F Wedekind & Timothy P Cripe. (2018) Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virotherapy 7, pages 65-77.
Read now
Read now
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now
Read now
Articles from other publishers (76)
Christelle Remy, Elodie Pintado, Marshall Dunlop, Shirley Schön, Patricia Kleinpeter, Homa Rozanes, Laetitia Fend, Renée Brandely, Michel Geist, Delphine Suhner, Eline Winter, Nathalie Silvestre, Claire Huguet, Peter Fitzgerald, Eric Quéméneur & Jean-Baptiste Marchand. (2023) Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus. Frontiers in Bioengineering and Biotechnology 11.
Crossref
Crossref
Ana Houel & Johann Foloppe. (2023) Les virus oncolytiques : acteurs et vecteurs de protéines thérapeutiques contre les tumeurs. médecine/sciences 39:11, pages 845-854.
Crossref
Crossref
Charlotte Lovatt & Alan L. Parker. (2023) Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple. Cancers 15:16, pages 4178.
Crossref
Crossref
Peter Kok-Ting Wan, Ricardo A Fernandes & Leonard W Seymour. (2023) Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?. Journal for ImmunoTherapy of Cancer 11:8, pages e006518.
Crossref
Crossref
Jun Xie, Shaowei Wang, Yunhong Zhong, Ming Gao, Xuezhang Tian, Liting Zhang, Dongli Pan, Qingsong Qin, Bing Wu, Ke Lan, Zhi-Jun Sun & Junjie Zhang. (2023) Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity. Molecular Therapy - Oncolytics 29, pages 61-76.
Crossref
Crossref
Sajad Najafi, Jamal Majidpoor & Keywan Mortezaee. (2023) The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade. Biomedicine & Pharmacotherapy 161, pages 114436.
Crossref
Crossref
Rūta Veinalde, Gemma Pidelaserra-Martí, Coline Moulin, Chin Leng Tan, Theresa E. Schäfer, Na Kang, Claudia R. Ball, Jonas Leichsenring, Albrecht Stenzinger, Lars Kaderali, Dirk Jäger, Guy Ungerechts & Christine E. Engeland. (2023) Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. Frontiers in Immunology 13.
Crossref
Crossref
Noelia Silva-Pilipich, Ángela Covo-Vergara, Lucía Vanrell & Cristian Smerdou. 2023. Viral Vectors in Cancer Immunotherapy. Viral Vectors in Cancer Immunotherapy
43
86
.
Mahdie Jafari, Maryam Kadkhodazadeh, Mina Bahrololoumi Shapourabadi, Nasser Hashemi Goradel, Mohammad Ali Shokrgozar, Arash Arashkia, Shahriyar Abdoli & Zahra Sharifzadeh. (2022) Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. Frontiers in Immunology 13.
Crossref
Crossref
Shu-Jin Li & Zhi-Jun Sun. (2022) Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. Cancer Letters, pages 215937.
Crossref
Crossref
Sepideh Safaei Ghaderi, Farhad Riazi-Rad, Elmira Safaie Qamsari, Salman Bagheri, Fatemeh Rahimi-Jamnani & Zahra Sharifzadeh. (2022) Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy. BMC Biotechnology 22:1.
Crossref
Crossref
S. Feola, S. Russo, E. Ylösmäki & V. Cerullo. (2022) Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacology & Therapeutics 236, pages 108103.
Crossref
Crossref
Xin Wang, Chao Wang, Zhe Qu, Chao Tian, Tiantian Wang, Yufa Miao, Hua Jiang, Lulu Li, Jiajia Liu, Rui Zhao, Xiaopeng Li & Xingchao Geng. (2022) Preclinical safety assessment of toxicity and biodistribution of oncolytic virus HSV-1 expressing human PD-1 antibody in mice. Regulatory Toxicology and Pharmacology 132, pages 105166.
Crossref
Crossref
Arianna Mencattini, Christine Lansche, Irina Veith, Philippe Erbs, Jean-Marc Balloul, Eric Quemeneur, Stéphanie Descroix, Fatima Mechta-Grigoriou, Gérard Zalcman, Cécile Zaupa, Maria Carla Parrini & Eugenio Martinelli. (2022) Direct imaging and automatic analysis in tumor-on-chip reveal cooperative antitumoral activity of immune cells and oncolytic vaccinia virus. Biosensors and Bioelectronics, pages 114571.
Crossref
Crossref
Hina Qayoom, Umar Mehraj, Shariqa Aisha, Shazia Sofi & Manzoor Ahmad Mir. 2022. Drug Repurposing - Molecular Aspects and Therapeutic Applications. Drug Repurposing - Molecular Aspects and Therapeutic Applications.
Ping Zhou, Xuchen Wang, Man Xing, Xi Yang, Mangteng Wu, Hongyang Shi, Caihong Zhu, Xiang Wang, Yingying Guo, Shubing Tang, Zhong Huang & Dongming Zhou. (2022) Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy. Molecular Therapy - Oncolytics 25, pages 236-248.
Crossref
Crossref
Yaomei Tian, Daoyuan Xie & Li Yang. (2022) Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Jacob P van Vloten, Kathy Matuszewska, Mark A A Minow, Jessica A Minott, Lisa A Santry, Madison Pereira, Ashley A Stegelmeier, Thomas M McAusland, Elaine M Klafuric, Khalil Karimi, Joseph Colasanti, D Grant McFadden, James J Petrik, Byram W Bridle & Sarah K Wootton. (2022) Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. Journal for ImmunoTherapy of Cancer 10:3, pages e004335.
Crossref
Crossref
Fabien Thoreau & Vijay Chudasama. (2022) Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chemical Biology 3:2, pages 140-169.
Crossref
Crossref
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Eric Quéméneur & Björn Frendéus. (2022)
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
+
T cell immunity to reject ‘cold’ tumors
. Journal for ImmunoTherapy of Cancer 10:1, pages e003488.
Crossref
Crossref
Xin Xie, Jingwen Lv, Wei Zhu, Chao Tian, Jingfeng Li, Jiajia Liu, Hua Zhou, Chunyang Sun, Zongfeng Hu & Xiaopeng Li. (2022) The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy. Translational Oncology 15:1, pages 101287.
Crossref
Crossref
Wei Zhu, Jingwen Lv, Xin Xie, Chao Tian, Jiajia Liu, Hua Zhou, Chunyang Sun, Jingfeng Li, Zongfeng Hu & Xiaopeng Li. (2022) The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma. Immunology Letters 241, pages 15-22.
Crossref
Crossref
Hikmat H. Assi, Chihunt Wong, Kimberly A. Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T. Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W. West, Jennifer H. Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin & W. Michael Kavanaugh. (2021) Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents. Cancer Immunology Research 9:12, pages 1451-1464.
Crossref
Crossref
Shuguang Zuo, Min Wei, Tiancheng Xu, Lingkai Kong, Bohao He, Shiqun Wang, Shibing Wang, Junhua Wu, Jie Dong & Jiwu Wei. (2021) An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. Journal for ImmunoTherapy of Cancer 9:12, pages e002843.
Crossref
Crossref
Elizabeth Appleton, Jehanne Hassan, Charleen Chan Wah Hak, Nanna Sivamanoharan, Anna Wilkins, Adel Samson, Masahiro Ono, Kevin J. Harrington, Alan Melcher & Erik Wennerberg. (2021) Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. Frontiers in Immunology 12.
Crossref
Crossref
Chao Tian, Jiajia Liu, Hua Zhou, Jingfeng Li, Chunyang Sun, Wei Zhu, Yuxin Yin & Xiaopeng Li. (2021) Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. Cancer Letters 518, pages 49-58.
Crossref
Crossref
Tengku Ibrahim Maulana, Elena Kromidas, Lars Wallstabe, Madalena Cipriano, Miriam Alb, Cécile Zaupa, Michael Hudecek, Birgit Fogal & Peter Loskill. (2021) Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. Advanced Drug Delivery Reviews 173, pages 281-305.
Crossref
Crossref
Peter Kok-Ting Wan, Anderson J. Ryan & Leonard W. Seymour. (2021) Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Molecular Therapy 29:5, pages 1668-1682.
Crossref
Crossref
Felicia Cao, Phuong Nguyen, Bangxing Hong, Christopher DeRenzo, Nino C. Rainusso, Tania Rodriguez Cruz, Meng‐Fen Wu, Hao Liu, Xiao‐Tong Song, Masataka Suzuki, Lisa L. Wang, Jason T. Yustein & Stephen Gottschalk. (2020) Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells. ADVANCES IN CELL AND GENE THERAPY 4:2.
Crossref
Crossref
Shuguang Zuo, Min Wei, Bohao He, Anxian Chen, Shiqun Wang, Lingkai Kong, Yenan Zhang, Gang Meng, Tiancheng Xu, Jingyi Wu, Fuming Yang, Hailin Zhang, Shibing Wang, Ciliang Guo, Junhua Wu, Jie Dong & Jiwu Wei. (2021) Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). EBioMedicine 64, pages 103240.
Crossref
Crossref
Loïs Coënon, Arthur Battistoni, Agathe Poupée-Beaugé, Stéphanie Germon & Isabelle Dimier-Poisson. (2021) Micro-organismes anti-cancéreux et armement. médecine/sciences 37:1, pages 47-52.
Crossref
Crossref
Michela Muscolini, Evelyne Tassone & John Hiscott. (2020) Oncolytic Immunotherapy: Can’t Start a Fire Without a Spark. Cytokine & Growth Factor Reviews 56, pages 94-101.
Crossref
Crossref
Lisa A. Santry, Jacob P. van Vloten, Jason P. Knapp, Kathy Matuszewska, Thomas M. McAusland, Jessica A. Minott, Robert C. Mould, Ashley A. Stegelmeier, Pierre P. Major, Sarah K. Wootton, James J. Petrik & Byram W. Bridle. (2020) Tumour vasculature: Friend or foe of oncolytic viruses?. Cytokine & Growth Factor Reviews 56, pages 69-82.
Crossref
Crossref
Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu & Weidong Han. (2020) Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system. Frontiers of Medicine 14:6, pages 726-745.
Crossref
Crossref
Mary Cook & Aman Chauhan. (2020) Clinical Application of Oncolytic Viruses: A Systematic Review. International Journal of Molecular Sciences 21:20, pages 7505.
Crossref
Crossref
Pei-Yang Hu, Xiao-Ming Fan, You-Ni Zhang, Shi-Bing Wang, Wei-Jie Wan, Hong-Ying Pan & Xiao-Zhou Mou. (2020) The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Applied Microbiology and Biotechnology 104:19, pages 8231-8242.
Crossref
Crossref
Shyambabu Chaurasiya, Yuman Fong & Susanne G. Warner. (2020) Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges. Cancers 12:6, pages 1699.
Crossref
Crossref
Christianne Groeneveldt, Thorbald van Hall, Sjoerd H. van der Burg, Peter ten Dijke & Nadine van Montfoort. (2020) Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses. Trends in Immunology 41:5, pages 406-420.
Crossref
Crossref
Tao Shi, Xueru Song, Yue Wang, Fangcen Liu & Jia Wei. (2020) Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Frontiers in Immunology 11.
Crossref
Crossref
Jahangir Ahmed, Louisa S Chard, Ming Yuan, Jiwei Wang, Anwen Howells, Yuenan Li, Haoze Li, Zhongxian Zhang, Shuangshuang Lu, Dongling Gao, Pengju Wang, Yongchao Chu, Chadwan Al Yaghchi, Joel Schwartz, Ghassan Alusi, Nicholas Lemoine & Yaohe Wang. (2020)
A new oncolytic
V
accinia
virus
augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery
. Journal for ImmunoTherapy of Cancer 8:1, pages e000415.
Crossref
Crossref
Yuhui Zhang & Zhuoming Liu. (2020) Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status. Current Pharmaceutical Design 25:40, pages 4251-4263.
Crossref
Crossref
G. V. Kochneva, G. F. Sivolobova, A. V. Tkacheva, A. A. Gorchakov & S. V. Kulemzin. (2020) Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer. Molecular Biology 54:1, pages 1-12.
Crossref
Crossref
Puyu Zou, Rui Tang & Mei Luo. (2020) Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis. International Immunopharmacology 78, pages 106050.
Crossref
Crossref
Maria Eugenia Davola, Alyssa Vito, Jiarun Wei, Nader El-Sayes, Samuel Workenhe & Karen Louise Mossman. 2020. Tumor Immunology and Immunotherapy – Integrated Methods Part A. Tumor Immunology and Immunotherapy – Integrated Methods Part A
231
250
.
Leonid Cherkassky, Rachel Grosser & Prasad S. Adusumilli. 2020. Cancer Regional Therapy. Cancer Regional Therapy
55
71
.
A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor & Kunle Odunsi. (2019) Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Yujie Zhu, Xiao Hu, Lin Feng, Zhenrong Yang, Lulin Zhou, Xinchun Duan, Shujun Cheng, Wen Zhang, Binlei Liu & Kaitai Zhang. (2019) Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1. Molecular Therapy - Oncolytics 15, pages 201-213.
Crossref
Crossref
Maria Cristina Ballesteros-Briones, Eva Martisova, Erkuden Casales, Noelia Silva-Pilipich, Maria Buñuales, Javier Galindo, Uxua Mancheño, Marta Gorraiz, Juan J. Lasarte, Grazyna Kochan, David Escors, Alfonso R. Sanchez-Paulete, Ignacio Melero, Jesus Prieto, Ruben Hernandez-Alcoceba, Sandra Hervas-Stubbs & Cristian Smerdou. (2019) Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses. Molecular Therapy 27:11, pages 1892-1905.
Crossref
Crossref
Y. Cai, Fei Wang, Q. Liu, Z. Li, D. Li & Z. Sun. (2018) A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma. Investigational New Drugs 37:5, pages 799-809.
Crossref
Crossref
Kevin Harrington, Daniel J. Freeman, Beth Kelly, James Harper & Jean-Charles Soria. (2019) Optimizing oncolytic virotherapy in cancer treatment. Nature Reviews Drug Discovery 18:9, pages 689-706.
Crossref
Crossref
Johann Foloppe, Juliette Kempf, Nicolas Futin, Jacqueline Kintz, Pascale Cordier, Christelle Pichon, Annie Findeli, Fabien Vorburger, Eric Quemeneur & Philippe Erbs. (2019) The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism. Molecular Therapy - Oncolytics 14, pages 1-14.
Crossref
Crossref
Antonio Marchini, Laurent Daeffler, Vitaly I. Pozdeev, Assia Angelova & Jean Rommelaere. (2019) Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Frontiers in Immunology 10.
Crossref
Crossref
Purushottam Lamichhane, Rahul Deshmukh, Julie Brown, Silvia Jakubski, Priyanka Parajuli, Todd Nolan, Dewan Raja, Mary Badawy, Thomas Yoon, Mark Zmiyiwsky & Narottam Lamichhane. (2019) Novel Delivery Systems for Checkpoint Inhibitors. Medicines 6:3, pages 74.
Crossref
Crossref
Patricia Kleinpeter, Christelle Remy-Ziller, Eline Winter, Murielle Gantzer, Virginie Nourtier, Juliette Kempf, Julie Hortelano, Doris Schmitt, Huguette Schultz, Michel Geist, Catherine Brua, Chantal Hoffmann, Yasmin Schlesinger, Dominique Villeval, Christine Thioudellet, Philippe Erbs, Johann Foloppe, Nathalie Silvestre, Laetitia Fend, Eric Quemeneur & Jean-Baptiste Marchand. (2019) By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1. Journal of Virology 93:11.
Crossref
Crossref
Venkatesh Sivanandam, Christopher J. LaRocca, Nanhai G. Chen, Yuman Fong & Susanne G. Warner. (2019) Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds. Molecular Therapy - Oncolytics 13, pages 93-106.
Crossref
Crossref
Mathieu J.F. Crupi, John C. Bell & Ragunath Singaravelu. (2019) Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses. Stem Cells 37:6, pages 716-723.
Crossref
Crossref
Alexander I. Glukhov, Dmitry A. Sivokhin, Daria A. Seryak, Tatyana S. Rodionova & Margarita I. Kamynina. (2019) Oncolytic Viruses As Immunotherapeutic Agents for the Treatment of Malignant Tumors. Annals of the Russian academy of medical sciences 74:2, pages 108-117.
Crossref
Crossref
Philipp Schuster, Georg Lindner, Sabrina Thomann, Sebastian Haferkamp & Barbara Schmidt. (2019) Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses. Cancers 11:5, pages 651.
Crossref
Crossref
Adam Ajina & John Maher. 2019. Cancer Immunotherapy. Cancer Immunotherapy
217
292
.
Michael P. O’Leary, Audrey H. Choi, Sang-In Kim, Shyambabu Chaurasiya, Jianming Lu, Anthony K. Park, Yanghee Woo, Susanne G. Warner, Yuman Fong & Nanhai G. Chen. (2018) Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. Journal of Translational Medicine 16:1.
Crossref
Crossref
Sonia Guedan & Ramon Alemany. (2018) CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge. Frontiers in Immunology 9.
Crossref
Crossref
Geetanjali Lal & Maitreyi S. Rajala. (2018) Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy. Cancer Gene Therapy 25:9-10, pages 216-226.
Crossref
Crossref
Praveen K. Bommareddy, Megha Shettigar & Howard L. Kaufman. (2018) Integrating oncolytic viruses in combination cancer immunotherapy. Nature Reviews Immunology 18:8, pages 498-513.
Crossref
Crossref
Ashley T Chen, Briana LR Samson, Mathieu JF Crupi & John C Bell. (2018) Oncolytic viruses: cytolytic agents, replicating immunotherapeutics or both?. Future Virology 13:7, pages 445-448.
Crossref
Crossref
Kwame Twumasi-Boateng, Jessica L. Pettigrew, Y. Y. Eunice Kwok, John C. Bell & Brad H. Nelson. (2018) Oncolytic viruses as engineering platforms for combination immunotherapy. Nature Reviews Cancer 18:7, pages 419-432.
Crossref
Crossref
Nikolas Tim Martin & John Cameron Bell. (2018) Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Molecular Therapy 26:6, pages 1414-1422.
Crossref
Crossref
J.F. de Graaf, L. de Vor, R.A.M. Fouchier & B.G. van den Hoogen. (2018) Armed oncolytic viruses: A kick-start for anti-tumor immunity. Cytokine & Growth Factor Reviews 41, pages 28-39.
Crossref
Crossref
Jacob P. van Vloten, Samuel T. Workenhe, Sarah K. Wootton, Karen L. Mossman & Byram W. Bridle. (2018) Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. The Journal of Immunology 200:2, pages 450-458.
Crossref
Crossref
Jennifer R. Hamilton, Gayathri Vijayakumar & Peter Palese. (2018) A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model. Cell Reports 22:1, pages 1-7.
Crossref
Crossref
William R. Strohl. (2017) Current progress in innovative engineered antibodies. Protein & Cell 9:1, pages 86-120.
Crossref
Crossref
Adam Ajina & John Maher. (2017) Prospects for combined use of oncolytic viruses and CAR T-cells. Journal for ImmunoTherapy of Cancer 5:1.
Crossref
Crossref
Eric Bartee & Zihai Li. (2017) In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade. Experimental Hematology & Oncology 6:1.
Crossref
Crossref
Kevin Hollevoet & Paul J. Declerck. (2017) State of play and clinical prospects of antibody gene transfer. Journal of Translational Medicine 15:1.
Crossref
Crossref
Chad R. Irwin, Mary M. Hitt & David H. Evans. (2017) Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses. Frontiers in Oncology 7.
Crossref
Crossref
Mee Y. Bartee, Katherine M. Dunlap & Eric Bartee. (2017) Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Research 77:11, pages 2952-2963.
Crossref
Crossref
Zong Sheng Guo, Zuqiang Liu, Stacy Kowalsky, Mathilde Feist, Pawel Kalinski, Binfeng Lu, Walter J. Storkus & David L. Bartlett. (2017) Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Frontiers in Immunology 8.
Crossref
Crossref